Clinical trial
IP3R Modulation by Cancer Genes Bcl-2 & PKM2 in Mesothelioma
NCT03558932 is registered in ClinicalTrials.gov with KU Leuven as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- IP3R Modulation by Cancer Genes Bcl-2 & PKM2 in Mesothelioma
- Lead sponsor
- KU Leuven
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- January 31, 2019
- Completion date
- June 30, 2024
- Enrollment
- 20 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
malignant mesothelioma